Nutex Health Inc. NUTX R2K

Q: What is the current share price of Nutex Health Inc. (NUTX)?

As of 2026-07-14 21:23 PDT, Nutex Health Inc. (NUTX) trades at $178.37 on NasdaqCM. Its 52-week range is $80.92 to $196.53.

Q: What is the market capitalisation of NUTX?

Nutex Health Inc. (NUTX) has a market capitalisation of $1.23B on NasdaqCM.

Q: What is the P/E ratio of NUTX?

NUTX trades at a trailing price-to-earnings (P/E) ratio of 13.05. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.90.

Q: What is the return on equity (ROE) of NUTX?

NUTX has a return on equity (ROE) of 53.65%. Its return on capital employed (ROCE) is 36.24%.

Q: Is NUTX a good stock to buy?

This page provides a data-driven analysis of Nutex Health Inc. (NUTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Care Facilities · United States

https://www.nutexhealth.com

Company Profile ↓

$178.37

+53.69% 1Y

Mkt Cap$1.23B

P/E13.05

P/B2.90

52W High$196.53

52W Low$80.92

Book Value$49.81

EPS (TTM)$13.67

Company Overview

Nutex Health Inc. operates as a healthcare services and operations company in the United States. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The Hospital segment develops and operates a network of micro hospitals, specialty hospitals, and hospital outpatient departments that offer healthcare services, including emergency room care, inpatient care, and behavioural health. It also provides imaging services, such as CT scan, X-ray, MRI, ultrasound, etc.; laboratory services; and onsite inpatient pharmacies. The PHM segment provides management, administrative, and other support services to its affiliated hospitals and physician groups by establishing and operating provider networks, such as independent physician associations (IPAs); and a cloud-based technology platform for IPAs. The Real Estate segment owns and leases land and hospital buildings. Nutex Health Inc. was founded in 2011 and is headquartered in Houston, Texas.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 53.6%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 36.2%.

Consistent Profit Growth

Net profit has compounded at 50.2% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 58.5% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 13.1, below the sector median of 25.4.

Healthy Margins

Operating margin of 37.5% supports profitability.

Recent Developments

Dec 2025 Revenue of $875.26M (+82.4% YoY); net profit $70.79M.
Trailing 12 Months Year-on-year growth — revenue +2.2%, earnings +95.9%.
5-Year Trend Long-term compounding — revenue CAGR 58.5%, profit CAGR 50.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	58.50%
1 Year:	2.20%

Compounded Profit Growth

5 Years:	50.22%
1 Year:	95.90%

Stock Price Performance

1 Year:	+53.69%
6 Months:	-4.19%
3 Months:	+67.85%
1 Month:	+21.33%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 84% of range

$80.92 $196.53

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)62.30 · Neutral

Price Performance

1M+21.33%

3M+67.85%

6M-4.19%

1Y+53.69%

Valuation vs Sector

P/E of 13.05 is below the sector median of 25.41 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Strong return on equity of 53.6%.
Healthy ROCE of 36.2%.
Compounding revenue at 58.5% over 5 years.
Profit CAGR of 50.2% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

13.05

Industry PE

25.41

Forward P/E

8.77

PEG Ratio

Book Value

$49.81

Price to Book

2.90

P/S

1.13

EV/EBITDA

2.97

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

58.50%

Profit 5Y

50.22%

Revenue (YoY)

2.20%

Earnings (YoY)

95.90%

Profitability & Returns

ROCE

36.24%

ROE

53.65%

ROA

28.59%

Profit Margin

10.95%

Op Margin

37.54%

Gross Margin

50.58%

EPS (Latest Qtr)

$6.52

EPS (TTM)

$13.67

Balance Sheet & Liquidity

Debt/Equity

0.79

Quick Ratio

3.00

Current Ratio

3.14

Debt

$349.09M

Total Assets

$957.32M

Current Assets

Working Capital

Ownership

Promoter Holding

29.06%

Chg in Prom Hold

FII / Inst Holding

42.52%

Chg in FII Hold

-0.01%

Financial Snapshot

Enterprise Value

$1.23B

Total Revenue (TTM)

$879.95M

EBITDA

$414.16M

Free Cash Flow

$168.75M

Operating Cash Flow

$272.68M

Shares Outstanding

6.88M

Gross Margin

50.58%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	NUTX Nutex Health Inc. R2K	178.37	13.05	$1.23B	0.00%	36.24%	53.65%	58.50%	50.22%
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	29.00M	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	137.30K	186.72K	153.95K	164.72K	180.32K	186.34K	400.56K	0	0	4.17K	-9.84K	11.06K	-3.74K	-4.17K	14.75K	43.68K	-1.79K	111.26K	266.50K	113.73K	139.14K	426.87K	29.14M	76.01M	35.82M	6.64M	-23.71M	530.32K	4.85M	9.65M	7.07M	13.21M	10.16M	22.56M	21.92M	141.63M	118.34M	124.92M	154.88M	91.73M
Operating Income	-134.97K	-201.25K	-184.34K	-143.19K	-86.80K	-121.83K	-161.94K	-64.51K	-75.70K	-163.21K	-1.25M	-711.94K	-411.97K	-489.01K	-367.01K	-925.91K	-374.71K	-906.13K	-939.91K	645.56K	1.78M	-4.15M	27.60M	74.46M	29.24M	-1.38M	-428.68M	-5.78M	-4.45M	-362.54K	-821.23K	-26.14M	1.45M	5.30M	9.66M	114.21M	80.66M	33.68M	130.37M	81.27M
Net Income	-161.58K	-75.27K	-185.76K	-144.90K	-51.65K	-74.85K	-238.87K	-96.05K	216.67K	-242.07K	-1.65M	6.33M	-610.03K	-726.25K	-608.52K	-968.16K	-570.37K	-857.63K	-1.12M	227.31K	1.76M	-4.48M	29.68M	74.49M	21.44M	-19.28M	-412.19M	-14.75M	-5.15M	-3.48M	-5.54M	-31.62M	-364.00K	-364.00K	-8.79M	61.70M	21.22M	-17.70M	55.44M	46.81M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.05	0.09	0.04	-0.03	-0.62	-0.02	-0.12	-0.79	-1.25	-7.47	-0.08	-0.07	-1.72	11.12	3.33	-2.95	7.76	6.52
R&D Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	181.25K	-	107.76K	114.88K	314.25K	73.83K	76.72K	59.63K	72.27K	73.75K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	874.77K	1.78M	1.59M	1.46M	1.07M	474.68K	0	23.17K	1.37M	1.37M	274.03M	331.53M	219.29M	247.65M	479.95M	875.26M
Gross Profit	483.19K	1.02M	810.38K	965.17K	603.28K	466.63K	0	-7.32K	859.36K	535.98K	157.61M	179.28M	15.42M	34.77M	196.26M	444.28M
Operating Income	-1.35M	-844.58K	-1.57M	-727.38K	-723.43K	-532.99K	-448.60K	-5.69M	-840.40K	-6.90M	153.17M	170.26M	-406.60M	-31.77M	130.70M	275.62M
Net Income	158.14K	-383.39K	-1.62M	250.49K	-684.34K	83.81K	-7.43M	582.06K	-950.13K	-7.12M	105.97M	132.59M	-424.78M	-45.79M	52.10M	70.79M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	0.18	0.22	-100.36	-10.39	9.69	10.48
R&D Expense	-	-	-	-	-	-	-	-	545.22K	768.10K	557.26K	285.88K	-	-	-	-

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	2.34M	1.89M	745.92K	1.07M	280.79K	7.64M	510.83K	3.33M	449.43K	6.69M	169.86K	394.65M	431.75M	398.25M	655.32M	918.52M
Total Equity	-	1.60M	305.70K	556.19K	-4.49K	1.56M	-5.87M	-997.22K	-1.50M	1.86M	-1.13M	114.65M	95.86M	61.45M	132.44M	329.45M
Cash & Equivalents	465.55K	224.80K	104.72K	26.87K	126.83K	122.29K	10.52K	9.45K	119.27K	1.07M	26.93K	36.12M	34.26M	22.00M	40.64M	185.57M
Long Term Debt	-	-	-	-	-	-	-	-	300.00K	0	0	78.82M	23.05M	26.31M	22.47M	29.17M
Total Liabilities	-	-	-	-	285.28K	6.08M	6.38M	-	1.95M	4.83M	1.30M	203.07M	311.42M	319.14M	466.79M	495.09M
Current Liabilities	351.62K	288.58K	440.22K	515.15K	285.28K	6.08M	6.38M	959.78K	1.04M	4.61M	1.15M	37.69M	54.86M	58.31M	154.22M	157.91M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-1.64M	-659.14K	-518.69K	-183.15K	159.20K	44.91K	-274.22K	-714.62K	-480.05K	-4.04M	86.67M	173.43M	50.61M	1.26M	23.15M	248.12M
Investing Cash Flow	1.22M	413.39K	417.74K	1.80K	-4.74K	1.83K	-9.99K	2.05K	-116.96K	-748.20K	-61.19M	-36.98M	-4.34M	-11.24M	-5.61M	-5.24M
Financing Cash Flow	22.89K	-	-19.13K	103.50K	-54.50K	-51.28K	172.44K	711.50K	704.57K	5.73M	-7.97M	-125.85M	-48.13M	-2.27M	1.09M	-97.95M
Capital Expenditure	5.69K	19.39K	8.06K	-	2.03K	1.80K	-	-	-0	-84.00K	-61.19M	-36.93M	-14.63M	-9.50M	-2.30M	-2.53M
Free Cash Flow	-1.63M	-639.75K	-510.63K	-	161.23K	46.70K	-	-	-480.05K	-4.12M	25.48M	136.51M	35.97M	-8.24M	20.85M	245.60M
Share Buybacks	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	5.00M

Ratios (Annual)

Figures in %.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	55.2%	57.1%	50.8%	66.1%	56.5%	98.3%	-	-31.6%	62.9%	39.2%	57.5%	54.1%	7.0%	14.0%	40.9%	50.8%
Operating Margin %	-153.9%	-47.3%	-98.7%	-49.8%	-67.7%	-112.3%	-	-24,574.5%	-61.5%	-504.8%	55.9%	51.4%	-185.4%	-12.8%	27.2%	31.5%
Net Margin %	18.1%	-21.5%	-101.9%	17.1%	-64.0%	17.7%	-	2,512.6%	-69.5%	-520.8%	38.7%	40.0%	-193.7%	-18.5%	10.9%	8.1%
ROE %	-	-23.9%	-531.2%	45.0%	15,238.1%	5.4%	126.6%	-58.4%	63.5%	-382.9%	-9,346.5%	115.6%	-443.1%	-74.5%	39.3%	21.5%
ROCE %	-67.8%	-52.7%	-514.6%	-130.8%	16,108.5%	-34.1%	7.6%	-240.3%	141.3%	-331.3%	-15,569.7%	47.7%	-107.9%	-9.3%	26.1%	36.2%

Shareholding Pattern

Insiders

29.06%

Institutions

42.52%

Public Float

59.94%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	5.51%	379.36K	$76.29M
2	Pertento Partners LLP	5.43%	373.97K	$75.20M
3	Vanguard Capital Management LLC	3.18%	219.13K	$44.07M
4	American Century Companies Inc	2.96%	203.45K	$40.91M
5	Topline Capital Management, LLC	2.58%	177.80K	$35.75M
6	State Street Corporation	1.79%	123.18K	$24.77M
7	Geode Capital Management, LLC	1.77%	122.11K	$24.56M
8	Millennium Management Llc	1.30%	89.57K	$18.01M
9	UBS Group AG	1.01%	69.57K	$13.99M
10	Winmill & Co. Inc	0.95%	65.35K	$13.14M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for NUTX

Google News Mon, 13 Jul 2026

The Technical Signals Behind (NUTX) That Institutions Follow - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxQVjNCQlBPVi1GTHA0cDlqdjQtbXZwNkVld1FRZUg0ZHh6cWY4Y0g5TF9UdV9pa01DRUtSamdzZ1F4a3VwTFlfNVR5ZWhZdjdMU1l2RGNCektaYk9VZGZidkltT1FRN3NYb2N2YlVHMF9uUmFkSUVQUVFQcm82cXNJZW9zOWVtZTVUWjJ2WG…

Google News Mon, 13 Jul 2026

Returns Matter: NUTX +214%, CORT +145%, GKOS +97% - Were These Biotech Stocks In Your Portfolio? - RTTNews

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQTkJEUngyaU1MZ0pBS2hqSlI5UE5QNHZQNzIzSkd4LUxlQnQ3VFVuMFA5dFJ5bHhTdGlCWm5KcVAyckJ1ZV8ySnYxODRCeTVYd1lHOU81TW5NTTdmb29HWVV3UHF3LTRoMWNBdVR1c05PN2FWUDl3WFR4MmZGV3RHaHlRRmMyQ0RVc201M1…

Google News hu, 09 Jul 2026

Nutex Health (NUTX) Is Down 6.7% After Arbitration-Driven Microhospital Profits Surge - Has The Bull Case Changed? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPTldGWHpIaDVYUUVveUpUQzhsVUI4Y25YcFhMYzNBSU1yOVFVZElKTjVLTkE3MlE2TE9hUzBxckhRLWx4bzl1MjJsVVdDZnp4ZUI0S29FR3h2UVhBaW5OTmxlUkJ3cTVZUHg4Z2xRd2FsUTJLb2l0SDZoaEpmdVUyME15U2hBYWdqT2dSLU…

Google News Mon, 04 May 2026

A Look At Nutex Health (NUTX) Valuation After Strong Q1 2026 Results And New Buyback Program - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxONk5VTHBIRHliSWh6Z1otd1c0dnRBSXBxSFU4ckFnYVQ2bUUydmRnTnNPNjM2UHE5MURGeERUdEhUWmtHeGJ6dks0R216VzBSdC0xcjdDTFNiQ2NTSmdWaG9naXRqWmdjUFM0bnk1U19DUEM4MXRGM0RfY0FJaHZaWlptUktYTUdoLU9Wd0…

Google News Wed, 01 Jul 2026

Nutex Health Has A Healthy Pulse And Shows Strong Signs Of Life For Further Gains - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQMS1JNzRlWS1tZExpNnQtMldZUHFGa3VXSml4dmtvbVJCRE1ObHFHWVhyRUlDMEtpR0tvZUt6dlI2MTdPLVRNNTFWRnk5UHJBV1d6WFpETGpydThMRWlYcmhZT3VpVzVZVDRxNFRsbzFSNFhMb0R5X1Q3UEg0Rmszc09Eb0JoR0FrbTFoZD…

Google News hu, 21 May 2026

Nutex Health Inc. (NUTX) — Deeply Undervalued Healthcare Services and Technology Company - The Acquirer's Multiple

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOYTZOVE5Kb3BlVGdYQy0zNjVLWmxDT25ndGxoZ2U4WDZWcjJFVnFRQlBSM21hSzF0M3IxV0t3SmNJUm5zTENvdGZVNEVlUEJkRDJXdjBZaTlxbnEtOTREQ1ZGVS1mTkNQSTU4Y0Z6WUJIZTBreFV4c2RfY1ZCTUtlYzV6WVFWTXRNcXBwSU…

NUTX — Frequently Asked Questions

What is the current share price of Nutex Health Inc. (NUTX)?

As of 2026-07-14 21:23 PDT, Nutex Health Inc. (NUTX) trades at $178.37 on NasdaqCM. Its 52-week range is $80.92 to $196.53.

What is the market capitalisation of NUTX?

Nutex Health Inc. (NUTX) has a market capitalisation of $1.23B on NasdaqCM.

What is the P/E ratio of NUTX?

NUTX trades at a trailing price-to-earnings (P/E) ratio of 13.05. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.90.

What is the return on equity (ROE) of NUTX?

NUTX has a return on equity (ROE) of 53.65%. Its return on capital employed (ROCE) is 36.24%.

Is NUTX a good stock to buy?

This page provides a data-driven analysis of Nutex Health Inc. (NUTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Nutex Health Inc. NUTX R2K

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

The Technical Signals Behind (NUTX) That Institutions Follow - Stock Traders Daily

Returns Matter: NUTX +214%, CORT +145%, GKOS +97% - Were These Biotech Stocks In Your Portfolio? - RTTNews

Nutex Health (NUTX) Is Down 6.7% After Arbitration-Driven Microhospital Profits Surge - Has The Bull Case Changed? - simplywall.st

A Look At Nutex Health (NUTX) Valuation After Strong Q1 2026 Results And New Buyback Program - Yahoo Finance

Nutex Health Has A Healthy Pulse And Shows Strong Signs Of Life For Further Gains - Seeking Alpha

Nutex Health Inc. (NUTX) — Deeply Undervalued Healthcare Services and Technology Company - The Acquirer's Multiple

NUTX — Frequently Asked Questions

What is the current share price of Nutex Health Inc. (NUTX)?

What is the market capitalisation of NUTX?

What is the P/E ratio of NUTX?

What is the return on equity (ROE) of NUTX?

Is NUTX a good stock to buy?

Explore More